- Home
- APRE
as 02-21-2025 4:00pm EST
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 21.2M | IPO Year: | 2019 |
| Target Price: | $15.50 | AVG Volume (30 days): | 35.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.15 - $8.85 | Next Earning Date: | 03-25-2025 |
| Revenue: | $1,310,839 | Revenue Growth: | 130.31% |
| Revenue Growth (this year): | 134.21% | Revenue Growth (next year): | -32.80% |
Latest Aprea Therapeutics Inc. Common stock News
APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing
TipRanks
16 days ago
Aprea Therapeutics provides update on existing patent portfolio
GlobeNewswire
17 days ago
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
GlobeNewswire
2 months ago
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Zacks
3 months ago
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
Simply Wall St.
3 months ago
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
3 months ago
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
3 months ago
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Zacks
4 months ago
Pacira (PCRX) Q3 Earnings Beat Estimates
Compare APRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APRE Aprea Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.